Tag: CYP
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors.
Natural...
Cynata Therapeutics gets approval for clinical trial on COVID-19
Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research.
In a statement to th...
Cynata Therapeutics’ stem cells could potentially help treat severe COVID-19 symptoms
Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to ...
Cynata Therapeutics has positive pre-clinical results using Cymerus stem cell platform to treat sepsis
Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results.
In a pre-clinical model of severe pneumonia-induced sepsi...
Fujifilm to commercialise Cynata Therapeutics’ mesenchymal stem cell technology
Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ (ASX: CYP) mesenchymal stem cell product which can treat...
Cynata Therapeutics reveals more positive pre-clinical cancer trial results
Biotechnology company Cynata Therapeutics (ASX: CYP) has published encouraging results from its ongoing preclinical program using its proprietary Cymerus platform.
The company said it was able to s...
Cynata Therapeutics looks to advance Cymerus stem cell treatment into phase 2 trials
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has said that it has “met all clinical endpoints” in its phase 1 trial of flagship drug CYP-001 – for the treatment of steroi...
Cynata study shows positive link between stem cells and cardiac function post-heart attack
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has announced positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a pre-clinical heart attack...
Phase 2 bone marrow transplant drug trial on the horizon for Cynata Therapeutics
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) may advance to a phase 2 clinical trial of a new stem cell drug if results of an initial two-stage trial continue ...
Cynata includes coronary artery disease into existing stem cell therapy research platform
Regenerative medicine company Cynata Therapeutics (ASX: CYP) has partnered up with the University of New South Wales (UNSW) in a bid to develop a stem cell treatment for coronary artery disease (CAD) ...
Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform
A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice of Allowance from the European Patent Office (EP...
Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy
Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in treating adverse reactions from chimeric antigen receptor T-...
Cynata receives key FDA approval to progress GvHD drug candidate
For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in the biotech space.
On this occasion, the FDA granted Cyna...
Cynata unveils promising results in treating graft versus host disease with stem cells
Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treating steroid resistant graft versus host disease.
After...
Cynata finds synergy with US-based biotech developer
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech company focusing on regene...
Cynata Therapeutics advance to second cohort in stem cell trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell product CYP-001, which began in November...
Cynata Therapeutics enrols first cohort for world first clinical trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of its stem cell product CYP-001 to treat steroid resistan...
